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Abstract
Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of the central retina affecting
approximately 1 in 30 Caucasians. Besides age and smoking, genetic variants from several gene loci have reproducibly been
associated with this condition and likely explain a large proportion of disease. Here, we developed a genetic risk score (GRS)
for AMD based on 13 risk variants from eight gene loci. The model exhibited good discriminative accuracy, area-under-curve
(AUC) of the receiver-operating characteristic of 0.820, which was confirmed in a cross-validation approach. Noteworthy,
younger AMD patients aged below 75 had a significantly higher mean GRS (1.87, 95% CI: 1.69–2.05) than patients aged 75
and above (1.45, 95% CI: 1.36–1.54). Based on five equally sized GRS intervals, we present a risk classification with a relative
AMD risk of 64.0 (95% CI: 14.11–1131.96) for individuals in the highest category (GRS 3.44–5.18, 0.5% of the general
population) compared to subjects with the most common genetic background (GRS 20.05–1.70, 40.2% of general
population). The highest GRS category identifies AMD patients with a sensitivity of 7.9% and a specificity of 99.9% when
compared to the four lower categories. Modeling a general population around 85 years of age, 87.4% of individuals in the
highest GRS category would be expected to develop AMD by that age. In contrast, only 2.2% of individuals in the two
lowest GRS categories which represent almost 50% of the general population are expected to manifest AMD. Our findings
underscore the large proportion of AMD cases explained by genetics particularly for younger AMD patients. The five-
category risk classification could be useful for therapeutic stratification or for diagnostic testing purposes once preventive
treatment is available.
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Introduction
Age-related macular degeneration (AMD) is a common
degenerative disease of the central retina and a leading cause of
severe vision impairment in Western societies [1]. Advanced forms
of AMD (late-stage AMD) are known as geographic atrophy (GA)
of the retinal pigment epithelium (RPE) or neovascular (NV)
complications with RPE detachment, scar formation, and
subretinal hemorrhage [2,3]. To date, effective therapeutic
intervention is available for active NV, while GA still remains
untreatable [4,5].
AMD is a complex disease influenced by genetic and
environmental factors with estimates of heritability varying from
45% to 71% [6]. So far, several AMD susceptibility loci have been
identified. Two loci are accounting for an estimated 50% of AMD
cases: complement factor H (CFH) on 1q32 and age-related
maculopathy susceptibility 2 (ARMS2)/HtrA serine peptidase 1
(HTRA1) on 10q26 [7,8]. Fine-mapping studies and functional
analyses at the CFH locus indicate at least three independent risk
variants [8–13]. At the ARMS2/HTRA1 region, a single risk
haplotype was found to fully explain the observed association [14].
A crucial role of the complement system in AMD pathogenesis
was further supported by subsequent candidate gene studies.
These studies identified risk-associated variants in or near three
additional complement genes including the complement compo-
nent 2 (C2)/complement factor B (CFB) [15], complement
component 3 (C3) [16,17] and complement factor I (CFI) [18].
In addition, variants in genes involved in the cholesterol and lipid
metabolism were also implicated in AMD susceptibility [19,20].
Strongest signals peaked near the hepatic lipase gene (LIPC)o n
chromosome 15q22 [19,20], the cholesterylester transfer protein
(CETP) and the lipoprotein lipase precursor (LPL) genes [19]. Also,
among the most replicated AMD risk variants are two coding
SNPs in the apolipoprotein E (APOE) gene [21,22]. A recent
genome wide association study established a significant association
of AMD with rs9621532, a variant intronic to synapsin III (SYN3)
and approximately 100 kb upstream of the tissue inhibitor of
metalloproteinases-3 gene (TIMP3) [19]. Finally, common varia-
tions near VEGFA and FRK/COL10A1 were associated with
AMD, further implicating angiogenesis as well as extracellular
matrix metabolism in AMD pathogenesis [23].
To predict the genetic risk in complex diseases, testing of single
susceptibility variants is generally of limited value [24]. In contrast,
genotyping and evaluating a series of independent disease
associated variants, a process also known as genetic profiling,
may be more appropriate [24]. This can be facilitated by a genetic
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37979risk score (GRS) which could simply represent the sum of risk
associated variants found in each individual. However, such an
approach may not be particularly effective in the presence of
greatly differing effect sizes of the respective variants [25].
Therefore, an extension to this model weighs each additional risk
allele by its effect size. For example, Seddon et al. (2009) calculated
a risk score for AMD based on 6 known genetic risk variants and
additional environmental factors. Their model revealed good
discriminatory power with a reported area-under-curve (AUC) of
the receiver-operating characteristic of 0.82 [26]. Other studies
reporting a GRS [19,20,23] primarily aimed at identifying novel
variants without using independent data or a cross-validation
approach and are thus likely biased to overestimate the effect of
these variants. The quantification of the genetic risk based on
frequently replicated AMD loci in a single study which is
independent from locus identification is still lacking.
Here, we present a genetic risk model for AMD, specifically the
late-stage forms of AMD, based on a large and well characterized
AMD case-control study group including 986 cases and 796
controls. We selected 13 genetic variants from eight gene loci that
have repeatedly been shown to be associated with AMD and
computed a genetic risk score. This was used to establish a
classification system that allows for discriminating subjects at high
and low genetic risk. Environmental variables such as smoking or
diet were not included in the model building.
Results
SNP selection based on published data and linkage
disequilibrium structure
Eight loci (CFH, ARMS2/HTRA1, CFI, CFB, C3, APOE,
LIPC and TIMP3) with 13 SNPs and established association with
AMD were included into our genetic risk score modeling (Table
S1). There were three further SNPs with reportedly established
association, which we did not select for the model: (i) at the CFH
locus, an association of four variants with AMD is known
(rs1410996, rs800292, rs1061170, rs6677604); however,
rs1410996 is present on two distinct haplotypes, each of which is
tagged by rs800292 (correlation r
2=0.473 to rs1410996 [27]) or
rs6677604 (r
2=0.283 to rs1410996 [27]), respectively [13], while
rs800292 and rs667604 are uncorrelated (r
2=0.008 [27]), (ii)
among the three highly correlated ARMS/HTRA variants
(rs10490924, rs11200638, and c.del443ins54; pairwise r
2=1),
rs10490924 was reported to fully capture the disease risk at this
locus [28]. We therefore selected rs1061170, rs800292 and
rs667604 at CFH and rs10490924 at the ARMS2/HTRA1 locus
yielding the 13 SNPs for model building.
Genotyping of SNPs in the Lower Frankonian AMD case-
control study
We genotyped the selected 13 SNPs as well as the three highly
correlated SNPs (to validate the correlations) in 986 cases and 796
controls from the Lower Frankonian AMD case-control study
(Table 1). All variants showed high genotyping quality with an
average call rate .99.5%. With the exception of rs1061170 at
CFH, all genotypes were in Hardy-Weinberg equilibrium in
controls (HWE, p.0.04). The variant rs1061170 was genotyped
twice with two independent assays yielding identical genotypes and
therefore persistent HWE violation in controls (p=0.002) [29].
There were no missing genotypes at the 13 variants for any
individual in the study.
Association of the selected 13 SNPs with AMD
For each SNP, association with AMD was computed using a
logistic regression model, unadjusted for age or gender (Table 2).
Sensitivity analysis additionally adjusting for age and gender
yielded similar results. Odds ratio (OR) estimates per AMD risk
increasing variant ranged from 1.14 [95% CI: 1.00–1.30] for
rs2285714 to 3.13 [95% CI: 2.68–3.68] for rs10490924 and were
significantly different from unity for all 13 variants demonstrating
sufficient statistical power in our study (Table 2). In a subgroup
analysis, AMD cases with GA (n=229) or NV (n=581) or mixed
GA+NV in one or both eyes (n=176) were compared to controls
using logistic regression for each variant separately (Figure S1).
Computing the genetic risk score
Based on the data from the 13 SNPs, we fit a multiple logistic
regression model (Figure 1). The odds ratios in this model ranged
from 1.070 to 4.063. This is, to our knowledge, the first study to
report these 13 variants together in one multiple logistic regression
accounting for other AMD risk variants. We computed a GRS for
each individual as the sum of AMD risk increasing alleles weighted
by the relative effect size of each SNP from the logistic model. We
added the alpha estimate of 210.13 to center the GRS on zero for
our study (see Methods). Cases had a significantly higher mean
GRS (1.61, 95% CI: 1.53–1.69) compared to controls (20.03,
95% CI: 20.12–0.06, p,0.01). The relative risk of AMD per
GRS unit approximated by the OR was 2.72 (95% CI: 2.46–3.01).
The mean GRS of our controls was slightly lower than the one for
the HapMap data representing a general population (0.00, 95%
CI: 20.14–0.14), which is in-line with our controls being selected
for having no AMD.
Good discriminative ability of the GRS
Computing the area-under-the-curve (AUC) of the receiver-
operating characteristic for the 13-SNP GRS, we observed good
ability to correctly classify those with and without the disease
(AUC=0.820, Figure 2). We also computed the AUC per locus
demonstrating that the impact by gene varied substantially, as
expected. The three SNPs at the CFH locus alone (rs800292,
rs1061170, rs6677604) showed the highest classification efficiency
(AUC=0.710), followed by rs10490924 at ARMS2/HTRA1
(AUC=0.684), and the remaining variants (AUC from 0.512 to
0.571) (Figure 2).
Table 1. Summary characteristics of the case-control study.
Cases Controls Total
Subjects 986 796 1782
GA
1 229 -
NV
2 581 -
Mixed GA+NV
3 176 -
Mean Age (S.D.) [in years] 78.7 (6.5) 78.3 (5.1) 78.5 (5.9)
Men [%] 34.1 39.3 36.4
Fraction smoker [%]
4,5 15.9 14.3
1Geographic atrophy.
2Neovascular AMD.
3Mixed GA+NV: GA and NV in the same eye or GA in one and NV in the second
eye.
4Smoking was defined as ever smoked more than 20 pack years.
5This variable was surveyed incompletely in cases and controls and thus was
not further considered in the analysis.
doi:10.1371/journal.pone.0037979.t001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37979Although we specifically avoided selecting the SNPs based on
association in our own data set but rather from the literature, there
could be a potential overestimation of the AUC: We estimated the
effect sizes per variant from our data and used these as weights for
the GRS. To evaluate this potential over-estimation, we
performed a sensitivity analysis via a cross-validation approach
by repeated (i=2000) random sub-sampling with 2/3rd of the
data for model building and 1/3rd for testing. The cross validated
AUC of 0.813 (95% CI: 0.813–0.814) is close to the one described
in our initial study (AUC=0.820).
Developing a parsimonious genetic risk score model
We evaluated whether a parsimonious model based on our data
could be developed. We thus explored several models by
subsequently excluding the loci with the weakest AUC and found
a model restricted to 10 variants with equally discriminatory
ability (AUC 0.820) and equal model fit (R
2=0.247) (Table 3).
This model could be of value for translational studies minimizing
the genotyping burden. Whether this is specific to our data set or
holds true for other study populations needs to be evaluated
further. It should be noted that all further analyses are based on
the 13-SNPs-GRS.
Distribution of the genetic risk score
The distribution of GRS for cases and controls as observed in
our study is given in Figure 3A. To provide a more realistic view
of the GRS distribution, the proportion of cases were weighted to
reflect a general distribution. For this modeling, an AMD
prevalence of 15% was assumed as reported for the general
population aged .85 years [30–32] (Figure 3B). The derived
GRS is comparable to the distribution estimated from individual
HapMap data (Figure 3B).
Genetic risk score by age groups, gender and AMD
subtype
We further investigated differences of the GRS between age-
groups (below or older than 75 years), men and women, or types of
AMD (GA, NV, or mixed GA+NV) using a significance level of
0.05/3 to account for the three subgroup tests performed.
Significant differences in mean GRS were found between
younger (1.87, 95% CI: 1.69–2.05) and older (1.45, 95% CI: 1.36–
1.54) AMD cases (p=8.7610
25), but there was no difference
between the age-groups among controls (p=0.18). The OR per
GRS unit was 3.06 (95%CI: 2.64–3.59) for younger and 2.71
(95% CI: 2.44–3.05) for older individuals. We also found that the
AUC restricted to the younger subjects (cases and controls) was
higher (0.852) than when only older subjects (cases and controls)
were included in the calculations (0.809).
Cases with mixed GA+NV had a significantly higher mean
GRS (1.87, 95% CI: 1.69–2.04) compared to NV cases (1.44, 95%
CI: 1.34–1.55, p=6.6610
25). It was also higher when compared
to GA cases (1.65, 95% CI: 1.48–1.83, p=0.03), although the
latter was statistically not significant when applying a conservative
Bonferroni-adjusted significance level of 0.05/3. The OR per
GRS unit was also higher for mixed GA+NV cases (OR=3.79,
95% CI: 3.13–4.67) than for NV cases (OR=3.79, 95% CI: 3.13–
4.67) or for GA cases (OR=2.84, 95% CI: 2.44–3.33). This effect
appeared to be independent of age, since mean age in GA (78.8
years, 95% CI: 77.9–79.6), NV (78.5 years, 95% CI: 77.9–79.0)
and mixed GA+NV (79.4 years, 95% CI: 78.4–80.3) was similar.
There was no significant difference in the GRS means between
men and women neither among cases nor among controls.
Figure 1. Risk estimates for each of thirteen AMD risk variants
from eight gene loci. Odds ratios (OR) per risk allele were derived
from multiple logistic regression models. Horizontal lines indicate 95%
confidence intervals.
doi:10.1371/journal.pone.0037979.g001
Figure 2. Area-under-the-curve of the receiver operating
characteristic for the 13-SNP genetic risk score and by gene
locus. Observed AUC was 0.820 and the locus-specific AUCs were
0.513, 0.524, 0.536, 0.547, 0.555, 0.571, 0.686 and 0.710 from bottom to
top.
doi:10.1371/journal.pone.0037979.g002
Table 3. Model fit and discriminative accuracy of
parsimonious models.
Model
1 Variants
2 R
2 AUC
13-SNP model 1,2,3,4,5,6,7,8,9,10,11,12,13 0.2475 0.820
- TIMP3 1,2,3,4,5,6,7,8,9,10,11,12 0.2475 0.820
- PLA2G12A 1,2,3,4,5,6,7,8,9,11,12 0.2454 0.819
- APOE 1,2,3,4,5,6,7,10,11,12 0.2411 0.816
- LIPC
3 1,2,3,4,5,6,7,8,9,10 0.2457 0.820
1SNPs from one additional locus at a time were omitted from the 13-SNP model
by starting with the locus with the smallest risk.
2Numbering corresponds to IDs in Table 2.
3This model contained the least number of SNPs without compromising R
2 or
AUC values.
doi:10.1371/journal.pone.0037979.t003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37979These subgroup analyses demonstrate a higher genetic risk of
the younger AMD patients compared to the older patients as well
as a higher genetic risk for those with mixed late-stage
manifestations (GA+NV) when compared to NV or GA alone.
Genetic risk groups and relative risk estimates
To establish a classification scheme, we formed five equally
sized intervals for the GRS spectrum (#21.79, (21.79)–(20.05),
(20.05)–1.70, 1.60–3.44, and .3.44; Table 4). The highest GRS
category (no. 5) contained 7.92% of AMD cases, but only 0.13%
of controls. In contrast, the two lowest GRS categories (nos. 1+2)
jointly contained only 9.8% of cases, but 48.7% of controls.
According to the HapMap data reflecting a general population,
the proportion of subjects in the two lowest risk groups combined
was 48.9% and 0.5% in the highest risk group. This is consistent
with the general population being a mixture of mostly controls and
only few cases.
The relative risks were approximated as ORs for each GRS
category using the middle category (no. 3) as reference (Table 4).
It can be seen that the OR is dramatically increased for category
four (OR=5.44, 95% CI=4.03–7.46) and even more for category
five (OR=64.00, 95% CI=14.11–1132.96). The odds ratios are
substantially decreased for categories two and one (OR=0.22,
CI=0.17–0.29 and OR=0.12, 95% CI=0.05–0.24) compared to
the reference. Thus, these GRS categories can effectively describe
genetic risk groups for AMD.
Due to the substantial differences found in mean GRS for
younger compared to older cases (see above), we derived these
ORs also separately by age-group. To avoid scarce data, risk
group one and two as well as four and five were combined to a low
and a high risk group, respectively (Table 4). This highlights the
higher genetic relative risk for AMD when restricting the analysis
to the younger (OR=12.66, 95% CI: 6.76–25.65) compared to
the older (OR=5.18, 95% CI: 3.70–7.38) subjects. Although the
95% confidence intervals overlap slightly, we observed a
significant difference (p=0.0194).
Modeled absolute risk for late-stage AMD
To reflect the anticipated situation in the general population
and to compute the absolute risk of AMD per GRS group, we
computed the fraction of late-stage AMD cases per GRS category
by (i) utilizing the fraction of cases and controls as observed in each
GRS category (Table 4) and (ii) weighting the fraction of cases
assuming various AMD prevalences (1%–15%). The fraction of
cases and the fraction of subjects of the modeled general
population (also for comparison in the HapMap sample) by
GRS category are shown in Table 5. The fraction of late-stage
AMD in the highest GRS group (absolute AMD risk) ranged from
38.6–91.7% depending on the assumed AMD prevalence which
were chosen to correspond to the various age-groups as reported
[30–32]. For example, in a general population with an AMD
prevalence of 10% approximately 90% of the persons in the
highest GRS group are expected to be affected by late-stage AMD.
Consequently, the genetic relative risk for subjects in the highest
GRS group (compared to the middle GRS group) is higher for
younger compared to the older AMD cases. However, the absolute
risk of AMD among subjects in the highest GRS group is higher
for the older population due to the higher AMD prevalence
among the older persons.
We again adopted the same cross-validation approach to
compute absolute risks since the effect sizes of the variants in the
GRS model, on which the absolute risk estimates are based, were
estimated from our study data. This approach yielded overall
similar estimates (Table S2).
Discussion
Based on a genetic risk score including 13 reported SNPs from
eight established AMD gene loci, we propose a five-category
classification system that effectively differentiates subjects with
high or low genetic risk. With this, we extend on earlier efforts to
predict the genetic risk for late-stage AMD [26,33–35]. Seddon et
al. described a risk score model for six genetic variants in four loci
also including environmental factors like BMI, smoking, age and
diet (sample size was 1.446 individuals of which 279 progressed to
AMD) [26]. Similarly, a study from Gibson et al. included 470
cases and 470 controls and reported an AUC of 0.83 (95% CI 0.81
to 0.86) using six SNPs in four loci and two environmental factors
[33]. A study by Spencer et al. investigated one variant in each of
four loci as well as age and smoking as environmental factors and
found an AUC of 0.84 (95% CI: 0.81–0.88) [35]. Jakobsdottir et
al. reported an AUC of 0.79 based on one SNP in each of three
loci [34]. This study consisted of around 1.000 family-based cases
and 429 controls as well as a case-control study with 187 cases and
Figure 3. Genetic risk score distribution in the study population and in a modeled population. AMD cases are shown in red, controls in
blue, while overlapping bars are shaded blue/red. (A) Genetic risk score distribution for cases (N=986) and controls (N=796) in the present study. (B)
Counts of cases in (A) were scaled to represent 15% of the total population (assumed as AMD prevalence of the 85–90 year old general population).
The density curve represents the risk score distribution in 381 European ancestry samples available through the 1000 Genomes Project (Release
20110521).
doi:10.1371/journal.pone.0037979.g003
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characterized and well powered case-control study and observed
an AUC of 0.820, which is sufficient to classify AMD patients and
controls into high risk and low risk groups [24]. Our study has not
contributed to the identification of any of the 13 SNPs as AMD
risk-increasing variants and would thus not be subject to winner’s
curse regarding the effect size. To our knowledge, this is a first
study to include most of the currently known genetic loci for their
value to predict late-stage AMD risk in a study that is independent
of the identification of any of these loci.
Interestingly, we find a higher relative risk of the CFB SNP
rs4151667 compared to CFH and ARMS2/HTRA1 risk-increas-
ing SNPs particularly in the multivariable logistic regression
model. This can also be seen in a previously published study
(Seddon et al., Table 4) [36], although it needs to be noted that the
models used in our and the published study differ in the sense that
Table 4. Five genetic risk groups and relative risk of AMD (ORs and 95% confidence intervals).
Genetic risk groups
GRS category 1 2 3 4 5
Sample size N=63 N=417 N=761 N=450 N=79
GRS interval #21.79 ]21.79,20.05] ]20.05,1.70] ]1.70,3.44] .3.44
Cases [%] 0.81 9.00 42.5 39.7 7.92
Cases ,75 years [%] 1.70 6.20 34.0 42.3 15.8
Cases .75 years [%] 0.54 9.96 45.2 38.9 5.38
Controls [%] 6.99 41.7 43.6 7.50 0.13
Frequency in HapMap
1 8.92 40.2 41.2 9.18 0.53
OR (95% CI) 0.12 (0.05–0.24) 0.22 (0.17–0.29) reference 5.44 (4.02–7.46) 64.00 (14.11–1131.96)
GRS categories low (1+2) 3 high (4+5)
Sample size N=480 N=761 N=529
GRS interval #20.05 ]20.05,1.70] .1.70
OR (95% CI) 0.21 (0.16–0.27) reference 6.41 (4.76–8.76)
,75 years: OR (95% CI) 0.19 (0.10–0.33) reference 12.66 (6.76–25.65)
.=75 years: OR (95% CI) 0.22 (0.16–0.29) reference 5.18 (3.70–7.38)
1Fraction of individuals in 1000 Genome Project European Ancestry Samples residing in risk groups.
doi:10.1371/journal.pone.0037979.t004
Table 5. Absolute risks for AMD by modeling a general population for various prevalences of AMD (reflecting various age-groups).
Modeled prevalence
(age-group [yrs])
1 Absolute risk of AMD by genetic risk group [%]
1 (low) 2 3 4 5 (high)
GRS interval #21.79 ]21.79,20.05] ]20.05,1.70] ]1.70,3.44] .3.44
% cases, modeled general
population
1% (65–69) 0.12 0.22 0.97 5.08 38.6
2.5% (70–74) 0.30 0.55 2.44 12.0 61.5
5% (75–79) 0.61 1.13 4.87 21.8 76.6
10% (80–84) 1.30 2.40 9.80 37.0 87.4
15% (.85) 2.00 3.70 14.7 48.3 91.7
% subjects, modeled general
population
1% 6.84 40.9 43.6 8.31 0.32
2.5% 6.68 40.1 43.8 8.50 0.34
5% 6.69 40.1 43.6 9.12 0.52
10% 6.38 38.5 43.5 10.7 0.91
15% 6.10 36.8 43.5 12.3 1.30
% subjects, HapMap population
2 8.92 40.2 41.2 9.18 0.53
1Approximate age-groups corresponding to the modeled prevalences for 65 and 79 years [30,31] and for those above 80 years [32].
2see Table 4.
doi:10.1371/journal.pone.0037979.t005
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largely focused on non-genetic factors. The smaller allele
frequency of the CFB SNP (1.8% in our cases, 6.7% in the
European ancestry 1000G individuals) compared to SNP frequen-
cies in CFH and ARMS2/HTRA1 results in a reduced power to
detect association and may explain why CFB SNP rs4151667 was
not among those detected first by AMD GWAS.
As expected, the mean GRS was significantly higher in cases
when compared to controls. Importantly, patients with late-stage
AMD diagnosed at an earlier age had a significantly higher mean
GRS than individuals that developed AMD later in life. This
strongly suggests that genetic predisposition influences disease
onset, which is also reflected in the higher relative AMD risk for
younger subjects with an OR of 12.66 (95% CI: 6.76–25.65) when
compared to older individuals with an OR of 5.18 (95% CI: 3.70–
7.38). The mean genetic risk score in our control group was
slightly lower but similar to the mean score in the HapMap sample
(including a total of 381 European subjects from CEU, GBR, IBS,
TSI and FIN, 1000 Genomes Project (Release 20110521, http://
www.1000genomes.org, accessed 2 May 2012).). The slight
discrepancy would be in-line with the fact that our controls were
specifically selected to reveal no signs of early or late-stage AMD.
Limitations of our study for risk prediction should be
acknowledged. First, the analysis was based on a case-control
study, which has no element of a prospective study or a nested
case-control study. The controls were often spouses of AMD
patients and thus non-genetic risk factors could not be studied due
to the known similarities among spouses regarding life style factors.
However, our AMD patients were virtually incident AMD cases
and thus the age at study entry is likely the age-at-diagnosis and
the best possible proxy for age-of-onset (allowing for a delay of
about 1–2 years between onset and diagnosis). In a case-control
setting, absolute risk or positive/negative predictive values cannot
be derived without making assumptions on the overall AMD
prevalence, which a prospective cohort study could estimate
directly. Thus, the predictive ability of the risk score groups greatly
depends on those assumptions. Second, it might be considered a
limitation but also a strength that our study included exclusively
late-stage AMD with NV or GA in one or both eyes as well as
highly-matched controls with no signs of early or late-stage AMD
in any eye. A strength as our data might exhibit less disease
misclassification than other studies, but a limitation as the genetic
relative risk could be overestimated if the genetic risk is larger for
subjects with both eyes affected than for those with only one
affected eye. Third, we had no independent and equally well
characterized data set available to separate model building from
testing although this is also the case for all other studies published
on AMD risk score model building [26,33,34]. Only one study
[35] reported a small replication study. We avoided selecting SNPs
for our model based on association signals in our own data but
rather selected SNPs from the literature. However, the SNP-
specific effect sizes utilized as weights in the genetic risk score
computation were still estimated in our data set. Thus, estimations
of AUC or absolute risk in the same data could lead to a slight
over-estimation of risk. We therefore adopted a cross-validation
approach as sensitivity analysis, which did not provide evidence of
remarkable over-estimation.
The highest genetic risk group of our proposed five-category
classification scheme can effectively identify subjects at high risk
for AMD. The specificity in this risk group was 99.9% (95% CI:
99.3%–100%). For example, our data and model suggest that
87.4% of subjects testing positive at some time in life for a high
genetic risk are likely to develop AMD in their mid-eighties
(positive predictive value). Thus, this group of individuals could
greatly profit from a sight-saving prevention or early intervention
program while only 13% of (false-positive) subjects would be
alarmed and treated unnecessarily. However, still a large number
of cases would be missed if this was established as a screening
method (sensitivity 8.0% (95% CI: 6.5%–9.9%), i.e. 92% of all
AMD cases would not be found in the highest risk group). Also
individuals in the second highest risk group could possibly profit
from early intervention, which would increase sensitivity to 47.6%
and decrease specificity to 91.2%. However, this would only be
acceptable, if the prevention/intervention is not harmful to the
59.9% of subjects treated and alarmed unnecessarily (40.1%
positive predictive value). These numbers are well in the range of
established screening tests, e.g. for prostate cancer by prostate
specific antigen (PSA) (positive predictive value=25.1%, sensitiv-
ity=72.1%, specificity=93.2%, [37]), albeit with a higher
predictive value at the cost of reduced sensitivity. Abnormal levels
of PSA are detected in about 10% of the male population, which is
comparable to the coverage of high risk group four and five [37].
Offering an effective prevention program to individuals in the
highest AMD risk group (approximately 400,000 individuals in
Germany alone), almost 10% of incident late-stage AMD could be
avoided. If individuals in risk groups four and five are included
(about 10% of the general population), up to 50% of future AMD
patients could be addressed.
So far, only the progression of the neovascular complications in
AMD can be slowed by treatment [38]. If disease progression to an
advanced neovascular form is detected early in high risk patients,
immediate intervention might prove essential to sustain full vision
for a more extended time. Accordingly, high risk individuals could
be advised to seek clinical follow-ups more frequently and could
also benefit from dietary recommendations, including the intake of
antioxidants [39] or omega-3 fatty acids [40,41]. Identification of
individuals at high risk for developing AMD may also help to
include defined candidates in clinical AMD trials and thus may
allow a better assessment of therapeutic effects.
In conclusion, our study provides a genetic risk score for late-
stage AMD from a well characterized case-control study
emphasizing the large proportion of disease explained by genetic
markers particularly for younger subjects. We propose a classifi-
cation scheme to identify subjects at high or low genetic risk that
might be suitable for risk stratification in therapy studies or genetic
screening once preventive treatment is available.
Methods
Ethics statement
This study followed the tenets of the declaration of Helsinki and
was approved by the Ethics Review Board at the University of
Wu ¨rzburg, Germany. Informed written consent was obtained
from each patient after explanation of the nature and possible
consequences of the study.
The study subjects
The case-control sample includes 986 AMD patients and 796
controls recruited from the Lower Frankonian area at the
University Eye Clinic of Wu ¨rzburg, Germany [14]. Controls were
often unaffected spouses or nonrelated acquaintances of cases of
similar age as the patient. All patients and controls were examined
by a trained ophthalmologist (CNK). Stereo fundus photographs
were graded according to standardized classification systems as
described previously [9,42,43]. Only patients with severe forms of
AMD (GA or NV) in at least one eye and signs of early AMD (e.g.
large soft drusen) in the other eye were included. The patients
were divided into three subgroups according to their type of late-
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in the severe eye and patients that had either GA in one eye and
NV in the other eye or that showed both late-stage forms in the
same eye (mixed GA+NV). Mean age in cases was 78.7 (66.5)
years and 78.3 (65.1) in controls. A total of 34.1% of cases and
39.1% of controls were male. Study characteristics are summa-
rized in Table 1.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
according to established protocols. Genotyping of SNPs was
achieved by direct sequencing, restriction enzyme digestion of
PCR products, TaqMan SNP Genotyping (Applied Biosystems,
Foster City, USA) or primer extension of multiplex PCR products
with detection of the allele-specific extension products by the
matrix-assisted laser desorption/ionization time of flight (MALDI-
TOF) mass spectrometry method (Sequenom, San Diego, USA)
(Table S3). Direct sequencing was performed with the Big Dye
Terminator Cycle Sequencing Kit Version 1.1 (Applied Biosys-
tems, Foster City, USA) according to the manufacturer’s
instructions. Reactions were analyzed with an ABI Prism Model
3130xl Sequencer (Applied Biosystems). TaqMan Pre-Designed
SNP Genotyping Assays (Applied Biosystems) were performed
according to the manufacturer’s instructions. Additionally, some
variants were genotyped by PCR followed by restriction enzyme
digestion (New England Biolabs, Ipswich, USA) and subsequent
restriction fragment length analysis. The c.del443ins54 variant in
the 39-region of the ARMS2 locus was genotyped by a single PCR
with oligonucleotide primers 59-ACTCATCACGTCATCAC-
CAAT-39 and 59-CTCTCTGCAGCCCTCATTTG-39 resulting
in distinct fragment sizes due to the presence or absence of the
deletion/insertion polymorphism.
Estimating genetic risk and model fit
Genotypes were coded as the number of AMD risk increasing
alleles (0, 1, and 2). Logistic regression analyses were carried out
using the R software [44]. Odds ratios (OR) per risk allele and
95% confidence intervals (95% CI) were calculated from the
estimated beta-coefficients to derive an approximate relative risk.
The goodness-of-fit of each model was assessed by calculating
McFaddens pseudo R
2 [45], which however, does not reflect the
variance explained by the model [46].
Computing the genetic risk score
Based on the intercept ‘‘a’’ and the single-SNP beta-coefficients
estimated using the logistic regression model including all SNPs at
once, the genetic risk score (GRS) was calculated as
GRS~az
X k
i~1
bi   xi ð1Þ
with k being the number of SNPs in the model and xi the genotype
of the ith SNP. Here, ‘‘a’’ denotes a constant that centers the risk
score distribution around zero and bi relates to the ith variant. The
odds ratio of the effect of the ith variant is thus given by exp(bi)
[19,23,26]. The mean GRS by age-group, sex, or AMD subtype
were compared based on the independent samples t test using the
R software [44] and differences were considered as significant, if
P,0.05/3 accounting for the three comparisons performed.
Assessing the discriminative ability
To estimate the ability of a potential genetic screening test to
discriminate between AMD cases and healthy subjects, we
computed the receiver-operating-characteristic (ROC) curve. This
involves ranking all subjects according to their GRS starting with
the smallest, computing sensitivity and specificity at each possible
GRS cut-off, and plotting sensitivity versus 1-specificity. The area-
under-the-curve (AUC) is a measure of how well the GRS cut-offs
can separate AMD cases from controls. We used the package
EPICALC [47] for AUC computations and forest plots were
generated with RMETA [48].
Internal validation by cross-validation
Although we have not selected the SNPs into the model based
on their association in our data set but rather with information
from the literature, there is a potential overestimation of the AUC
due to the fact that we used the SNP effect sizes to weigh the risk
alleles when computing the GRS. Thus, we conducted a sensitivity
analysis using a cross-validation approach to derive AUC estimates
that are not subject to this bias to compare with the original data
AUC. We randomly assigned 2/3
rd of the data to the model
building (to compute the effect sizes and thus establish the GRS
model) and 1/3
rd of the data to testing (to compute the AUC and
positive predictive values) ([49,50]). We repeated this 2000 times
and computed the average AUC as an unbiased estimate.
Modeling of the absolute risk by GRS group
In order to derive the fraction of cases in the five GRS
categories as expected in the general population (corresponding to
the absolute AMD risk) from the number of cases (N_cases=986)
and controls (N_controls=796) in our case-control study, we
weighted the number of AMD cases in our study by
weight~
prevalence  N controls
1-prevalence ðÞ
 N cases
ð2Þ
where prevalence denotes the fraction of AMD cases in the general
population, that we chose to reflect previously reported preva-
lences of AMD in the various age groups (65–69 years: 1%, 70–74
years: 2.5%, 75–79 years: 5%, 80–84 years: 10% and .85 years:
15%) [30–32]. These were also used to compute positive and
negative predictive value for the highest GRS category as a
screening test for AMD. The cross-validation approach described
above was also adopted for a sensitivity analysis to compute
unbiased absolute risk.
Supporting Information
Figure S1 Risk estimates for 16 AMD associated
variants by disease subtypes. Logistic regression models
were fitted with all patients (N=986), GA cases only (N=229),
NV cases only (N=581) or mixed GA+NV cases (N=176) versus
controls (N=796). Odds ratio estimates (OR) are given per risk
allele; horizontal bars indicate 95% confidence intervals and the
arrow indicates that the boundary extends below 1 or above 6.
(TIF)
Table S1 Published genetic variations associated with
AMD.
(DOC)
Table S2 Cross validated absolute risks for late stage
AMD in different risk groups in the modeled population.
(DOC)
Table S3 Primers and methods used for genotyping.
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